Stoke Therapeutics' (STOK) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

Stoke Therapeutics (NASDAQ:STOK - Get Free Report)'s stock had its "overweight" rating reissued by investment analysts at Cantor Fitzgerald in a research note issued on Thursday, Benzinga reports.

STOK has been the subject of several other research reports. JPMorgan Chase & Co. raised their price target on Stoke Therapeutics from $6.00 to $13.00 and gave the stock a "neutral" rating in a research report on Tuesday, March 26th. HC Wainwright restated a "buy" rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, March 26th. TD Cowen raised Stoke Therapeutics from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 26th. Canaccord Genuity Group lifted their target price on Stoke Therapeutics from $18.00 to $21.00 and gave the company a "buy" rating in a research note on Tuesday, March 26th. Finally, Wedbush lifted their target price on Stoke Therapeutics from $13.00 to $17.00 and gave the company an "outperform" rating in a research note on Tuesday, March 26th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Stoke Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $19.63.

Stoke Therapeutics Trading Down 5.0 %

Shares of NASDAQ STOK traded down $0.64 during trading hours on Thursday, reaching $12.17. The stock had a trading volume of 892,511 shares, compared to its average volume of 972,429. The firm has a market cap of $563.47 million, a price-to-earnings ratio of -5.13 and a beta of 0.77. Stoke Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $16.40. The firm has a 50-day moving average of $7.05 and a 200-day moving average of $5.35.

Insider Buying and Selling

In related news, General Counsel Jonathan Allan sold 5,126 shares of the stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $13.20, for a total value of $67,663.20. Following the completion of the transaction, the general counsel now owns 2,598 shares of the company's stock, valued at $34,293.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, General Counsel Jonathan Allan sold 5,126 shares of the firm's stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $13.20, for a total transaction of $67,663.20. Following the completion of the sale, the general counsel now owns 2,598 shares of the company's stock, valued at $34,293.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Barry Ticho sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $4.80, for a total transaction of $48,000.00. Following the sale, the insider now directly owns 6,981 shares of the company's stock, valued at approximately $33,508.80. The disclosure for this sale can be found here. Insiders sold 32,741 shares of company stock valued at $223,115 over the last quarter. Corporate insiders own 12.30% of the company's stock.

Institutional Trading of Stoke Therapeutics

Several hedge funds have recently modified their holdings of the company. Ensign Peak Advisors Inc bought a new stake in shares of Stoke Therapeutics during the first quarter valued at approximately $25,000. Point72 Hong Kong Ltd bought a new stake in shares of Stoke Therapeutics during the first quarter valued at approximately $27,000. Great West Life Assurance Co. Can grew its stake in shares of Stoke Therapeutics by 46.7% during the first quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company's stock valued at $28,000 after purchasing an additional 1,078 shares during the last quarter. Dorsey & Whitney Trust CO LLC bought a new stake in shares of Stoke Therapeutics during the third quarter valued at approximately $43,000. Finally, UBS Group AG bought a new position in Stoke Therapeutics in the third quarter valued at approximately $47,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.